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The gut microbiome is rapidly becoming the focus of interest as a possible factor involved
in the pathophysiology of neuropsychiatric disorders. Recent understanding of the
pathophysiology of schizophrenia emphasizes the role of systemic components,
including immune/inflammatory and metabolic processes, which are influenced by and
interacting with the gut microbiome. Here we systematically review the current literature on
the gut microbiome in schizophrenia-spectrum disorders and in their animal models. We
found that the gut microbiome is altered in psychosis compared to healthy controls.
Furthermore, we identified potential factors related to psychosis, which may contribute to
the gut microbiome alterations. However, further research is needed to establish the
disease-specificity and potential causal relationships between changes of the microbiome
and disease pathophysiology. This can open up the possibility of. manipulating the gut
microbiome for improved symptom control and for the development of novel therapeutic
approaches in schizophrenia and related psychotic disorders.
Keywords: gut microbiota, schizophrenia, early life events, inflammation, microbiota metabolites, stressINTRODUCTION
The gut microbiome has recently received considerable interest, due to its potential role in
maintaining health and in the pathophysiology of chronic diseases (1). Our understanding of the
involvement of the gut microbiome in diseases is fast increasing due to the emergence of new
molecular biological techniques (2). In healthy individuals, the gut microbiome, which consists of
more than 100 trillion bacteria (3, 4), has a symbiotic relationship with enteric cells to influence
physiological function (5). The gut microbiome is highly variable between healthy individuals (3),
with twins only sharing 50% of their species-level bacterial taxa (6). This interindividual difference isAbbreviations: C-section, Cesarean delivery; CoR, completeness of reporting; GABA, gamma-aminobutyric acid; HPA,
hypothalamic pituitary adrenal; MIA, maternal immune activation; NMDA, N-methyl-D-aspartate; OTU, operational
taxonomic units; PCoA, principal coordinate analysis; PICRUSt, Phylogenetic Investigation of Communities by
Reconstruction of Unobserved States; PRISM-P, Preferred Items for Reporting Systematic Reviews and Meta-analysis
Protocols; RoB, risk of bias; SCFA, short-chain fatty acid; TNF, tumor necrosis factor.
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Kraeuter et al. Gut Microbiome in Psychosisshaped through host-extrinsic, host-intrinsic, and environmental
factors (2, 3). Host-extrinsic factors include lifestyles, such as
physical activity, cultural habits, medication, and diet (2).
Environmental factors altering the microbiome include the
local environment and maternal transmission (2). Host-
intrinsic factors, which might shape the gut microbiota, are
genetics, sex, innate, and adaptive immunity, as well as
metabolic factors, i.e., body mass index (2, 7). Although
interindividual differences exist in healthy individuals, studies
have demonstrated clear separations of the gut microbiome in
chronic diseases such as individuals with allergies (8–10), celiac
disease (11), gastric cancer (12), inflammatory bowel disease (13,
14) including Crohn’s disease (15) and ulcerative colitis (3, 16),
obesity (3, 17, 18), anorexia (17, 19), and type 2 diabetes mellitus
(20) compared to healthy controls. The functional importance of
the gut microbiome was demonstrated by the transfer of the gut
microbiome from obese to germ-free mice resulting in
obesity (21).
Bidirectional communication has been well established between
the gut and the brain and its importance for maintaining neuronal,
hormonal and immunological homeostasis has been recently
demonstrated (22). A damage to the integrity of the gut-brain
communication results in altered brain function and behavior (23).
More recently, the importance of the gut-brain axis has been
highlighted as a possible contributing factor, among many others,
such as genes, early environment and nutrition, in the development
of neuropsychiatric disorders (5, 22).
Schizophrenia is a heterogeneous, chronic neurodevelopmental
psychiatric spectrum disorder influenced by a hitherto poorly
understood interaction between genetic and environmental factors
(24). It affects about 1 in 100 people (1%) worldwide (25). A variety
of different pathophysiological mechanisms have been proposed,
such as the dopamine hyperactivity in certain brain systems (26, 27),
impaired glutamate neurotransmission (28), and a disruption of the
brain glucose and energy metabolism (29–32). It has been
conceptualized that multiple environmental “hits” on the
background of a genetic predisposition are required for its
development (33, 34). Genome-wide association studies have
shown that schizophrenia is a polygenic disorder with a complex
array of contributing risk loci across the allelic frequency spectrum
(35, 36). Environmental events throughout development and
adulthood, such as viruses before birth, method of delivery, birth
complications, and psychosocial traumas, are important in the
pathophysiology of schizophrenia (27) and the shaping of the gut
microbiome (37–39). Most recently, a study demonstrated that mice
receiving feces from individuals with schizophrenia showed a
behavioral phenotype that is consistent with that have been seen
in animal models of schizophrenia and depression (40). This finding
demonstrates that a constituent of the fecal matter have effect of
brain function and behavior of the host and strengthen the
suggestion that the microbiome might contribute to behavioral
symptoms in psychosis (41).
In this systematic review, we summarize the most recent
findings on the gut microbiome in psychosis, including animal
models and clinical data. Furthermore, we identified potential
factors particular to psychosis, which may contribute to theFrontiers in Psychiatry | www.frontiersin.org 2altered gut microbiome. The methodology of the studies
covered was not described in details as these were extensively
reviewed elsewhere (42). Compared to previous reviews (43) we
provide detailed discussion of factors such as antipsychotic use,
lifestyle and environmental factors as well as the potential
pathological role of the microbiome in psychosis relevant to
microbial changes.METHODS
Eligibility and Inclusion Criteria
We included original articles investigating preclinical and clinical
studies exploring the fecal microbiome in animal models of
schizophrenia and individuals of all ages with psychosis or at
high risk and schizophrenia along with respective controls. Only
studies published in English were included without a date
restriction throughout the database search.
Database Search Strategy
This study followed the Preferred Items for Reporting Systematic
Reviews and Meta-analysis Protocols (PRISM-P) (44). One
author (AKK) conducted a Scopus, Web of Science, and
PubMed database searches until the cut-off date of 14/02/2019.
In all databases, free-text terms included (microbiota OR
gastrointestinal microbiome OR microbiome OR microbio*)
AND (schizophreni* OR “Dementia Praecox” OR psychotic OR
schizoaffective OR psychoses OR psychosis). The search was
limited to original articles, and therefore we excluded reviews,
meta-analyses, and systematic reviews. The reference lists of
eligible papers were manually screened for further relevant articles.
Report Selection
One of the authors (A-KK) determined the eligibility of papers
by screening titles and abstracts for relevance. Eligible
documents were then read as a whole to analyze if the articles
matched the inclusion criteria. Excluded articles were documented,
and reasons were given for exclusion.
Data Extraction
A-KK extracted information from relevant publications such as
animal and patient characteristics. Study characteristics for
animal experiments included strain, sex, number, age, and
weight of animals and “schizophrenia” induction method,
length of study, the timing of fecal sample collection,
microbiota, and other findings of the study. Human studies
were characterized by the number of participants, gender, age,
exclusion and inclusion criteria, microbiota findings, and other
findings within the study.
SYRCLE’s Risk of Bias Analysis
The overall risk of bias (RoB) was assessed in animal studies
using an adapted SYRCLE’s risk of bias tool (45). All ten entries
of the SYRCLE’s RoB tool were assessed by the authors (A-KK,
RP) relating to selection, performance, detection, attrition,
reporting, and other biases (45). All individual entries wereAugust 2020 | Volume 11 | Article 799
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parameter was determined “unclear” if the item was not mentioned
in the publication. The only exception to this was item 8, where ‘not
mentioned’ was scored “high RoB.” For one article, it was not
feasible to assess housing conditions (items 3, 4, and 5) due to the
nature of that particular animal model of schizophrenia (46).
Furthermore, studies were assessed for quality by answering the
categories: (1) conflict of interest stated, (2) power analysis or
sample size calculation, (3) experiment blinding at any level, and (4)
randomization at any level.
STROBE Risk of Bias Analysis
Human studies were assessed using adapted STROBE assessment
criteria, including 32 subsections, which were scored for all six
studies. A-KK and RP assessed the completeness of reporting
(CoR) score (CoR (%)=(yes/(yes+no))*100) by answering each
recommendation in the STROBE statement with “yes” or “no.”
Microbiome Methodological Consideration
All studies were investigate for their CoR for microbiome
relevant methodology. Categories range from sample
preparation, handling to analysis of samples. The CoR score
was calculated as described in the previous section. The overall
CoR score was calculated for all studies, animal studies alone and
human studies alone.RESULTS
Database Search
The initial search yielded 763 documents, including one additional
record identified through other sources. After exclusion of
duplicates, 673 articles remained and were included for evaluation
of titles or abstracts, which resulted in 69 records for full-text article
review. During full-text article review, 60 articles were excluded
because they were not original research articles (reviews, n=43; letter
to the editor, n=1; book chapter, n=1), referred to microbiomes
other than the gut microbiome (oropharyngeal, n=4; blood, n=2),
was not a mouse model of schizophrenia (n=4), or reported no
control (n=5). One additional article was found during scanning of
the references. This search resulted in nine articles included in this
systematic review (Figure 1).Study Characteristics
Animals
Preclinical publications included within this review used three
different types of translationally validated animal models. A
neurodevelopmental model, the maternal immune activation
(MIA), which takes advantage of the finding that maternal
infection during pregnancy increases the risk of developing
schizophrenia in the offspring, by injecting pregnant females
with viral mimic polyriboinosinic–polyribocytidilic acid (Poly I:
C), which disrupts prenatal and early postnatal development
(48). A pharmacological model, the N-methyl-D-aspartate
(NMDA) receptor hypofunction model induced by administration
of the NMDA receptor antagonist phencyclidine, is based on theFrontiers in Psychiatry | www.frontiersin.org 3findings that the administration of NMDA antagonists
[phencyclidine (PCP) and ketamine] induce schizophrenia-like
behaviors (49, 50). Social isolation is a major “psychological”
stressor that has been used over the years to induce a behavioral
and neurochemical phenotype corresponding to schizophrenia (51).
This alteration has long-lasting effects on the brain and behavior
(48). Articles describing preclinical results included 144 male Lister-
Hooded rats investigated the microbiome in a pharmacological,
phencyclidine (52), and a developmental model (social isolation)
(46) (Table 1). In the neurodevelopmental model, the gut
microbiome was assessed in ten C57/Bl6 offspring in the MIA
group and ten respective controls with unknown sex (53). The
two studies using rats had similar size rats of 100-130 g (46, 52); only
one study reported that rats were 24 days old (46). C57BL/6N mice
were six weeks of age (53). All studies analyzed microbiome using
16S rRNA gene MiSeq-based high throughput sequencing (46, 52,
53). All studies were supported by various sources of funding (46,
52, 53).
Human
Six eligible studies were identified, which investigated high-risk
and ultrahigh-risk (UHR) individuals (4), first-episode psychosis
(54), first-episode schizophrenia (55), and individuals with
chronic schizophrenia (40, 56, 57) all compared to healthy
controls (Table 2). High-risk (or at risk) state is the clinical
presentation of those considered at risk of developing psychosis
or schizophrenia. Such states were formerly considered as
prodromes, emerging symptoms of psychosis, but this view is
no longer maintained as a prodromal period can not be
confirmed unless the emergence of the condition has occurred.
Individuals are considered UHR for psychosis if they meet a set
of standardized criteria including presumed genetic vulnerability
(Trait), or a recent history of Attenuated Psychotic Symptoms
(APS) or Brief Limited Intermittent Psychotic Symptoms
(BLIPS) Yung, McGorry (58, 59). First-episode and chronic
schizophrenia are defined in Table 2. A total of 321 patients
and 273 healthy controls were investigated. All studies reported
no significant differences between the experimental and control
group for age, sex, and weight. Age varied widely between studies
due to different stages of the disorder from 20.47 ± 4.57 to 54.7 ±
10.7. Common exclusion criteria included factors potentially
influencing the gut microbiome such as gastrointestinal and
endocrine disorders, previous antibiotic or probiotic treatment,
alcohol and substance abuse. Inclusion criteria varied greatly
between studies due to different baseline diagnostic criteria.
Risk of Bias
Animals
Of the 30 SYRCLE entries of all three studies, 15 (50%) were low
RoB, 2 (6.6%) were high RoB, 10 (33.3%) were unclear, and 3
(10%) were considered not feasible (Figure 2).
Quality Assessment
All studies were randomized and acknowledged their funding
source (Figure 3). However, none of the studies reported how the
sample size was estimated during the design of the experimentAugust 2020 | Volume 11 | Article 799
Kraeuter et al. Gut Microbiome in Psychosis(Figure 3). One study failed to report if the experimenter was
blinded at any level.
Human Studies
The analysis included a total of 192 entries (32 STROBE entries
per study). Of the 192 STROBE entries, 139 (72.4%) entries were
scores “Yes” for CoR, and 53 (27.6%) were scored “No” for CoR
(Figure 4).
Microbiome Methodological Consideration
The analysis included a total of 63 entries (7 entries per study).
Of the 63 entries, 47 (74.6%) entries were scores “Yes” for CoR,Frontiers in Psychiatry | www.frontiersin.org 4and 16 (25.4%) were scored “No” for CoR (Figure 5). One study
within this review did not use caecum samples rather than fecal
samples (46). None of the animal studies reported the amount
used for microbial analysis (46, 52, 53). Reporting for the amount
of fecal sample varied within human studies with two studies
failing to report amount used (40, 55). Similarly, mixed results
were found for storage information given with two animal
studies (52, 53) and one human study (55) not reporting the
storage of samples between collection and analysis. Three studies
did not report target regions (53–55). All studies reported the
sequencing platform used (4, 40, 46, 52–57) and all human
studies reported the DNA extraction protocol and PCR primersFIGURE 1 | Flow diagram (47).August 2020 | Volume 11 | Article 799
Kraeuter et al. Gut Microbiome in PsychosisTABLE 1 | Gut microbiota changes in animal models of schizophrenia.
Strain, Sex (n),
Age (weight)
Disease
induction and
length of study
Fecal sample col-
lection timing
Microbiota changes Other findings Comments
Pyndt Jørgensen,
Krych (52)
EXP1-4: Lister-
Hooded rats, M
(24), NA (100-
130g)
EXP1-4: SZ: 5
mg/kg free base
PCP i.p.
Control: vehicle
i.p.
EXP4: addition
ampicillin
through the
drinking water
Length of study
EXP1: 7 days
PCP and 7 day
washout
EXP2: 7 days
PCP and 28 day
washout
EXP3: 7 days
PCP and 49 day
washout
EXP4: 7 days
PCP and 7 day
washout
EXP1: Day 16
EXP2: Day 37
EXP3: Day 58
EXP4: Caecum:
Day 19
EXP1:
No difference
• a-diversity
Altered
• b-diversity
Increased
• Roseburia (Phylum: Firmicutes)
• Odoribacter (Phylum: Bacteroidetes)
Increased Locomotor activity positively
correlated with:
• Lachnospiraceae (Phylum: Firmicutes)
• Clostridiaceae (Phylum: Firmicutes)
• Roseburia (Phylum: Firmicutes)
• Clostridium (Phylum: Firmicutes)
• Odoribacter (Phylum: Bacteroidetes)
EXP2:
No difference
• a-diversity
• b-diversity
Increased
• unclassified genus bellowing to the S24-
7 family (Phylum: Bacteroidetes)
• Dorea (Phylum: Firmicutes)
EXP1-3:
Increased
• Locomotion
EXP1 and 2:
Decreased
• NOR
performance
EXP3:
No Change
• NOR
performance
EXP4:
Improved
• Reversed
cognitive deficits in
No change
• Locomotion
EXP1 and 4:
• NOR on day 15
and16
• Locomotor
activity on day 18
EXP2:
• NOR on day 36
and 37
• Locomotor
activity on day 39
EXP3:
• NOR on day 57
and 58
• Locomotor
activity on day 60
Dunphy-Doherty,
O’Mahony (46)
Lister-Hooded
rats, M (24), 24
days (100-130g)
Social isolation
Control: group
housed
Length of study
63 days
Caecum:
Day 86/87
No difference
• a-diversity
• b-diversity
Increased:
• Phylum: Actinobacteria
• Rhodococcus (Phylum: Actinobacteria)
• Negativicutes (Phylum: Firmicutes)
• Corynebacteriales (Phylum:
Actinobacteria)
• Bacillales (Phylum: Firmicutes)
• Selenomonadales (Phylum: Firmicutes)
• Nocardiaceae (Phylum: Actinobacteria)
• Bacillaceae (Phylum: Firmicutes)
• Veillonellaceae (Phylum: Firmicutes)
• Prevotellaceae UCG-001 (Phylum:
Bacteroidetes)
• Bacillus (Phylum: Firmicutes)
• Defluvitaleaceae UCG-011 (Phylum:
Firmicutes)
• Eubacterium oxidoreducens group
(Phylum: Firmicutes)
• Marvinbryantia (Phylum: Firmicutes)
• Veillonella (Phylum: Firmicutes)
Decreased
• Clostridia (Phylum: Firmicutes)
• Clostridiales (Phylum: Firmicutes)
• Clostridiacae group 1 (Phylum:
Firmicutes)
• Peptostreptococcaceae (Phylum:
Firmicutes)
• Lachnospiraceae UCG-009 (Phylum:
Firmicutes)
• Ocillospira (Phylum: Firmicutes)
• Papillibacter (Phylum: Firmicutes)
*Correlations described in text
Increased
• Locomotion
(OF)
Decreased
• Defecation (OF)
• Freezing first,
24,48 shocks (CFR)
• Cells in dentate
gyrus dual labeled
for BrdU and NeuN
• Il-6 and IL-10 in
hippocampus
No Change
• Rearing (OF)
• Grooming (OF)
• NOR
• EPM
• Second shock
(CFR)
• Corticosterone
(restrained)
• IL-1b or TNF-a
• 56 rats received
5-bromo-20-
deoxyuridine
• Open field
(day59)
• Locomotor
activity noval area
(day 65)
• NOR (day 66)
• EPM (day73)
• Conditioned
Freezing Response
(day79/80/81)
• Restrained
Stress and Sample
collection (day 86/
87)
(Continued)Frontiers in Psychiatry | www.frontiersin.org 5 August 2020 | Volume 11 | Article 799
Kraeuter et al. Gut Microbiome in Psychosisused (4, 40, 54–57). However, none of the animal studies
reported the DNA extraction protocol (46, 52, 53) and one
animal study failed to report PCR primers used. The major of
publications within this review used 16S rRNA sequencing (4, 40,
46, 52, 53, 56, 57). Two studies used alternative techniques such
as RT-qPCR for 16 s primers (54) or qPCR for 16 s primers (55).
Studies, which reported target region investigated V3 or V4
regions (4, 46, 52, 56, 57). The preferred sequencing platform was
the Illumina Miseq platform (4, 46, 52, 54, 56, 57).
Overall, we found a CoR score of 74.6% for all studies, which a
large divide between CoR of animal (CoR: 47.6%) and human
studies (CoR: 88.1%).
Microbiome Analysis and Its Relationship
to Behavior
In the following sections, we summarize the taxonomic changes
in validated animal models of schizophrenia (46, 52, 53) and
high-risk and UHR individuals (4), first-episode psychosis (54),
first-episode schizophrenia (55), and individuals with chronic
schizophrenia (40, 56, 57), all compared to healthy controls. The
reviewed publications consistently report OTU (operational
taxonomic unit) values, alpha and beta diversity, terms not
frequently used outside the field of microbiome research. OTU
is used to cluster sequences based on their similarities (60). Alpha
diversity (within-sample) is the species number (richness) andFrontiers in Psychiatry | www.frontiersin.org 6distribution (evenness) within a host organism or habitat,
showing “how many different species were found,” i.e., how
many different bacteria are in a healthy individual, which can be
measured using Shannon diversity index and Faith ’s
Phylogenetic Diversity (56). Beta diversity (between-samples)
answers the question “How different is the microbial composition
in one environment compared to another?”, calculated using Bray-
Curtis dissimilarity and unweighted UniFrac and ordinated using
principal coordinate analysis (PCoA).
Within the Results section we will be reporting changes
according to phylum levels, this structure will remain for the
discussion, however we will be discussion changes at lower
taxonomic units within the phylum sections of the discussion.
Details of the taxonomic changes are described in Tables 1 and 2
and Figure 6 showing reduced abundance in orange, increased
abundance in purple with lighter shades of orange and purple to
signify that only preclinical evidence is available.
Animals
One study investigated the gut microbiota of C57BL/6N
offspring in the neurodevelopmental MIA model (53). MIA
mice, from as early as three weeks, showed increased intestinal
permeability, which was shown through increased translocation
of fluorescein isothiocyanate-dextran across the intestinal
epithelium (53). Alpha diversity is the species richness within aTABLE 1 | Continued
Strain, Sex (n),
Age (weight)
Disease
induction and
length of study
Fecal sample col-
lection timing
Microbiota changes Other findings Comments
Hsiao, McBride
(53)
C57BL/6N
offspring, Sex:
unknown,
Microbiota:
n=10/group,
Behavior: 16-
75/group), 6
weeks at
behavioral
testing
Pregnant
C57BL/6N mice
were injected
i.p. on E12.5
with saline or 20
mg/kg poly(I:C)
Length of study
9 weeks
Unknown No difference
• a-diversity
Altered
• b-diversity
Increased
• unclassified Bacteriodales (Phylum:
Bacteroidetes)
• Porphyromonadaceae (Phylum:
Bacteroidetes)
• Prevotellaceae (Phylum: Bacteroidetes)
• Lachnospiraceae (Phylum: Firmicutes)
Decreased
• Ruminococcaceae (Phylum: Firmicutes)
• Erysipelotrichaceae (Phylum: Firmicutes)
• Alcaligenaceae (Phylum: Proteobacteria)
No change
• Clostrodia (Phylum: Firmicutes)
• Bacteroidia (Phylum: Bacteroidetes)
Increased
• Intestinal
permeability (3
week old offspring)
• Gene
expression
(CLDN15)
• IL-6 mRNA and
protein
• Repetitive
behavior (marbles
buried)
Decreased
• Gene
expression (TJP1,
TJP2, OCLN, and
CLDN8)
• IL-12p40/p70
• MIP-1a
• Centre entries
and time spent (OF)
• PPI
• Communication
(ultrasonic
vocalization)
• Sociability
(3CST)
• Social
preference (3CST)
Normalization with
probioticAugust 2020 | VoluSZ, schizophrenia; PCP, phencyclidine; NOR, novel object recognition; OF, open field test; CRF, conditioned freezing task; CST, chronic social defeat.me 11 | Article 799
TABLE 2 | Gut microbiota changes in schizophrenic patients and at risk individuals.
her findings Comments
ce:
d gender
ms in UHR
levels in UHR
• HC: no family history of
mental illness
• 37 HC did not agree with 1H-
MRS
•
1H-MRS: 7 HR and 2 UHR
excluded
ce:
nder and several
arameters (BMI,
, high and low
proteins, glucose,
triglycerides)
ent less active
s-no association:
l activity
psychosis
n of antipsychotic
tion of risperidone,
or olanzapine
f different food
the week prior to
lection
• Food habits and physical
activity assessed
• Fecal sample not collected if:
antibiotic use during the past 3
months, chronic gastrointestinal
disease, gastrointestinal surgery,
or diagnosed celiac disease.
• Microbiota clustering at intake
was significantly associated with
remission at follow-up
(Continued)
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7Patient
Characteristics
(N, Gender,
Age)
Exclusion/Inclusion
criteria
Microbiota
analysis
Microbiota findings at Baseline compared to control Ot
He,
Kosciolek
(4)
• HR (41M,
40F, 21.67 ±
5.75)
• UHR (15M,
4F, 20.47 ±
4.57)
• HC (37M,
32F, 23.13 ±
3.89)
Exclusion:
• Gastrointestinal and
endocrine diseases
• Diagnosis with psychotic
disorder and corresponding
treatments
• Last 3 month: alcohol,
antibiotics, probiotics or any
other oral or injectable
medications
• One measure
at baseline
No difference
• a-diversity
Altered:
• b-diversity in HR and UHR
Increased in UHR:
• Clostridiales (Phylum: Firmicutes)
• Lactobacillales (Phylum: Firmicutes)
• Bacteroidales (Phylum: Bacteroidetes)
• Lactobacillus (Phylum: Firmicutes)
• Prevotella (Phylum: Bacteroidetes)
• Lactobacillus ruminis (Phylum: Firmicutes)
No Change
• HR group
No differen
• Age an
Increased:
• Sympt
• Choline
Schwarz,
Maukonen
(54)
• FEP (16M,
12, 25.9 ± 5.5)
• HC (8M, 8F,
27.8 ± 6.0)
Exclusion:
• Substance-induced
psychosis and psychotic
disorders due to general medical
conditions
Inclusion:
• Score of at least 4 in the item
assessing delusion (Usual
Thought Content) and
hallucinations (Brief Psychiatric
rating scale)
• FEP: Morning
of interview
• HC: Sample at
home and
delivered them
within a few hours
to the laboratory
• Baseline, 2
and 12 month
No difference
• a-diversity
Increased:
• Phylum Actinobacteria
• Rhizobiales (Phylum: Proteobacteria)
• Bacillales (Phylum: Firmicutes)
• Lactobacillaceae (Phylum: Firmicutes)
• Halothiobacillaceae (Phylum: Proteobacteria)
• Brucellaceae (Phylum: Proteobacteria)
• unclassified Micrococcineae (Phylum: Actinobacteria)
• Lactobacillus (Phylum: Firmicutes)
• Tropheryma (Phylum: Actinobacteria)
• Halothiobacillus (Phylum: Proteobacteria)
• Saccharophagus (Phylum: Proteobacteria)
• Ochrobactrum` (Phylum: Proteobacteria)
• Deferribacter (Phylum: “Deferribacteres”)
• Halorubrum (Phylum: Euryarchaeota)
• Lactobacillus aciddophilus (Phylum: Firmicutes)
• Lactobacillus grasser (Phylum: Firmicutes)
• Lactobacillus saliva (Phylum: Firmicutes)
• Lactobacillus reuter (Phylum: Firmicutes)
• Lactobacillus fermen (Phylum: Firmicutes)
• Desulfosporosinus acidphilus (Phylum: Firmicutes)
• Bifidobacterium dentium (Phylum: Actinobacteria)
• Tropheryma whipplei (Phylum: Actinobacteria)
• Ochrobactum anthropi (Phylum: Proteobacteria)
• Bartonella clarridgeiae (Phylum: Proteobacteria)
• Franisella hispaniensis (Phylum: Proteobacteria)
• Nitrosocococcus halophilus (Phylum: Proteobacteria)
• Brucella canis (Phylum: Proteobacteria)
• Saccharophagus degradans (Phylum: Proteobacteria)
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8Patient
Characteristics
(N, Gender,
Age)
Exclusion/Inclusion
criteria
Microbiota
analysis
Microbiota findings at Baseline compared to control Oth
• Halothiobacillus neapolitanus (Phylum: Proteobacteria)
• Deferribacter desulfuricans (Phylum: “Deferribacteres”)
Decreased:
• Negativicutes (Phylum: Firmicutes)
• Selenomondales (Phylum: Firmicutes)
• Veillonellaceae (Phylum: Firmicutes)
• Anabaena (Phylum: Cyanobacteria)
• Nitrosospira (Phylum: Proteobacteria)
• Gallionella (Phylum: Proteobacteria)
• Thermococcos gammatolerans (Phylum: Euryarchaeota)
• Leuconostoc gasicomitatum (Phylum: Firmicutes)
• Nitrosomonas spp. (Phylum: Proteobacteria)
• Anabaena variabilities (Phylum: Cyanobacteria)
• Gallionella capsiferriformans (Phylum: Proteobacteria)
• Chlorobium chlorochromate (Phylum: Chlorobi)
• Nitrosospira multiformis (Phylum: Proteobacteria)
• Xenorhabdus nematophila (Phylum: Proteobacteria)
In active SZ patients
Increased:
• Lactobacillaceae (Phylum: Firmicutes)
Decreased:
• Veillonellaceae (Phylum: Firmicutes
*Correlations described in text
Shen, Xu
(57)
• SZ (M36,
F28, 42 ± 11)
• HC (M35,
F18, 39 ± 14)
Exclusion:
• Last 3 month: Disease that
may affect the stability of gut
microbiota
• Last 6 months: antibiotics,
glucocorticoids, cytokines, large
doses of probiotics and
biological agents
• Gastroscopy, colonoscopy or
gastrointestinal barium meal
• Last 5 years: major
gastrointestinal tract surgery
• Activity limitation
• Changes in dietary habits
• Alcohol abuse or
dependence
Inclusion:
• SZ patients were diagnosed
according to ICD-10 and
received antipsychotic treatment
in hospital or outpatient clinic
• One measure
at baseline
No difference
• a-diversity
Altered:
• b-diversity
Increased:
• Phylum Proteobacteria
• Phylum Fusobacteria
• Gammaproteobacteria (Phylum: Proteobacteria)
• Fusobacteriia (Phylum: Fusobacteria)
• Enterobacteriales (Phylum: Proteobacteria)
• Fusobacteriales (Phylum: Fusobacteria)
• Aeromonadales (Phylum: Proteobacteria)
• Prevotellaceae (Phylum: Bacteroidetes)
• Enterobacteriaceae (Phylum: Proteobacteria)
• Succinivibrionaceae (Phylum: Proteobacteria)
• Fusobacteriaceae (Phylum: Fusobacteria)
• Veillonellaceae (Phylum: Firmicutes)
• Lactobacillaceae (Phylum: Firmicutes)
• Succinivibrio (Phylum: Proteobacteria)
• Megasphaera (Phylum: Firmicutes)
• Acidaminococcus (Phylum: Firmicutes)
No differenc
• Age, BM
tobacco use
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Characteristics
(N, Gender,
Age)
Exclusion/Inclusion
criteria
Microbiota
analysis
Microbiota findings at Baseline compared to control Oth
• Illness duration ≤10 years
and received antipsychotic drugs
treatment > 6months; psychiatric
symptoms were steady >3
months, and the PANSS
evaluated the rate of change
≤20% and the total score of
PANSS ≤60.
• Collinsella (Phylum: Actinobacteria)
• Clostridium (Phylum: Firmicutes)
• Klebsiella (Phylum: Proteobacteria)
• Citrobacter (Phylum: Proteobacteria)
• Methanobrevibacter (Phylum: Euryarchaeota)
• Fusobacterium (Phylum: Fusobacteria)
• Lactobacillus (Phylum: Firmicutes)
• Phascolarctobacterium (Phylum: Firmicutes)
• Desulfovibrio (Phylum: Firmicutes)
• Collinsella aerofaciens (Phylum: Actinobacteria)
• Bifidobacterium adolescentis (Phylum: Actinobacteria)
• Prevotella stercorea (Phylum: Bacteroidetes)
• Bacteroides fragilis (Phylum: Bacteroidetes)
• Lactobacillus mucosae (Phylum: Firmicutes)
• Lactobacillus ruminis (Phylum: Firmicutes)
Decreased:
• Phylum Firmicutes
• Clostridia (Phylum: Firmicutes)
• Clostridiales (Phylum: Firmicutes)
• Streptococcaceae (Phylum: Firmicutes)
• Alcaligenaceae (Phylum: Proteobacteria)
• Lachnospiraceae (Phylum: Firmicutes)
• Streptococcus (Phylum: Firmicutes)
• Blautia (Phylum: Firmicutes)
• Coprococcus (Phylum: Firmicutes)
• Roseburia (Phylum: Firmicutes)
• Roseburia faecis (Phylum: Firmicutes)
• Blautia producta (Phylum: Firmicutes)
• Collinsella plebeius (Phylum: Actinobacteria)
• Bacteroides eggerthii (Phylum: Bacteroidetes)
*Correlations described in text
Yuan,
Zhang (55)
• FES (M23,
F18, 23.1 ± 8.0)
• HC (M20,
F21, 24.7 ± 6.7)
Exclusion
• Autoimmune diseases, heart
diseases, hepatobiliary and
gastrointestinal diseases, blood
diseases, diabetes neurological
diseases, or psychiatric diseases
other than FES
• Pregnant or lactating women
• A history of using any
antibiotic or anti-inflammatory
agent, or probiotic in the past
month
• A significant change in the
• Baseline,
6,12,24 weeks of
risperidone
treatment
Increased:
• Clostridium coccoides group (Phylum: Firmicutes)
Decreased:
• Bifidobacterium spp. (Phylum: Actinobacteria)
• Escherichia coli (Phylum: Proteobacteria)
• Lactobacillus spp. (Phylum: Firmicutes)
No Change:
• Bacteroides spp. (Phylum: Bacteroidetes)
After 24 weeks risperidone-
Increased:
• Bifidobacterium spp. (Phylum: Actinobacteria)
• Escherichia coli (Phylum: Proteobacteria)
After 24 we
Increased:
• Weight
• BMI
• Fasting s
glucose
• Triglycer
• LDL
• HOMA-I
• Serum le
• SODe
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• 21 patients on antipsychotics
at study onset
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mpal GABA
SZ were treated with a single
antipsychotic drug:
• Clozapine (n = 15)
• Risperidone (n = 14)
• Olanzapine (n = 9)
• Chlorpromazine (n = 5)
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10Patient
Characteristics
(N, Gender,
Age)
Exclusion/Inclusion
criteria
Microbiota
analysis
Microbiota findings at Baseline compared to control Ot
living environment or diet in the
past month
• Significant diarrhea or
constipation in the past month.
Healthy controls had the same
exclusion criteria as patients; in
addition, they had no previous
history of any psychiatric
diseases.
Inclusion
• FES based on the DSM-IV
criteria
• Never been on antipsychotic
medication
• PANSS total score N60
points
• Born through normal vaginal
delivery
• Normal body weight (BMI:
18.5–23.0).
Decreased:
• Clostridium coccoides group (Phylum: Firmicutes)
• Lactobacillus spp. (Phylum: Firmicutes)
No Change:
• Bacteroides spp. (Phylum: Bacteroidetes)
*Correlations described in text
Nguyen,
Kosciolek
(56)
• SZ or
schizoaffective
disorder (14M,
11F, 52.9 ±
11.2)
• HC (15M,
10F, 54.7 ±
10.7)
Exclusion
• Other current major DSM-IV-
TR Axis I diagnoses
• Alcohol or other substance
(other than tobacco) (within 3
months prior to enrollment)
• Diagnosis of dementia
• Intellectual disability disorder,
• Major neurological disorder
• Any medical disability that
interfered with a subject’s ability
to complete study procedures
• One measure
• Home stool
collection kits
(samples returned
via mail)
No difference
• a-diversity
Altered:
• b-diversity
Increased:
• Anaerococcus (Phylum: Firmicutes)
Decreased:
• Phylum Proteobacteria
• Haemophilus (Phylum: Proteobacteria)
• Sutterella (Phylum: Proteobacteria)
• Clostrodium (Phylum: Firmicutes)
*Correlations described in text
No differen
• Age, ge
Increased:
• BMI (ho
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• Psychia
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• Anxiety
• Smokin
• Medica
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Zheng,
Zeng (40)
• SZ (63)
• HC (69)
Exclusion
• Physical or other mental
disorders
• Illicit drug use
• Antibiotics/probiotics within 1
month of study
• Decreased:
• a-diversity
Altered:
• b-diversity
Increased:
No differen
• Age, ge
Increased:
• Serum
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Kraeuter et al. Gut Microbiome in Psychosis
Frontiers in Psychiatry | www.frontiersin.org 11host organism or habitat, showing “how many different species
were found,” i.e., how many different bacteria are in a healthy
individual. This remains unaltered in MIA mice. Beta diversity,
which reflects the species diversity to contribute to species
evenness between microbial communities, i.e., how different
was the diversity of bacteria between healthy controls compared
to diseased individuals, was significantly altered by the MIA.
PCoA (index of beta-diversity) showed that MIA samples
clustered significantly differently to control samples, indicating
different gut microbiome composition compared to control
animals. The primary drivers of the gut microbiome changes
concerning diversity were the classes Clostridia and Bacteroidia.
MIA significantly altered families in the phyla Bacteroidetes,
Firmicutes, and Proteobacteria compared to controls (53)
(Figure 6 and Table 1).
Subchronic administration of phencyclidine for seven days, a
pharmacological model of schizophrenia, significantly separated
the microbiota population compared to controls (beta-diversity)
(52). Locomotor activity was increased in phencyclidine treated
animals with seven days and four weeks wash-out period
compared to controls, which indicates a schizophrenia-like
behavioral phenotype (52) (Table 1). Seven days after
treatment with phencyclidine, no change was found in alpha-
diversity. However, a weak but significant alteration was found in
beta-diversity compared to controls using the PCoA-analysis,
which indicates the separation of the microbial communities.
Phencyclidine-treated animals showed increased abundance in
genera belonging to the phyla Firmicutes and Bacteroidetes (52)
(Figure 6 and Table 1). Four weeks after phencyclidine
treatment, no changes in alpha-diversity and beta-diversity
were found between groups. However, the abundance of
genera within the phyla Firmicutes and Bacteroidetes were
significantly increased in phencyclidine-treated animals (52)
(Figure 6 and Table 1).
Social isolation resulted in hyperactivity, anxiety-like behavior,
and impaired contextual learning and memory, as well as reduced
IL-6 and IL-10 levels in the hippocampus (46). Although no
significant changes for alpha-diversity and beta-diversity were
found, socially isolated animals showed a trend toward a decrease
in alpha diversity and a trend towards differential clustering of
microbial communities (beta diversity) (46) (Figure 6 and Table 1).
Social isolation increased the abundance ofActinobacteria at phylum
level. At class, order, family, and genus level social isolation altered
the abundance to both directions of the phyla Firmicutes,
Actinobacteria, and Bacteroidetes (46) (Figure 6 and Table 1).
In summary, the preclinical studies using translationally valid
models for schizophrenia show somewhat inconsistent findings
with the decreased abundance of the phylum Proteobacteria
emerging as a partially shared feature (53). At the same time,
Actinobacteria (46) and Bacteroidetes (46, 52, 53) were increased,
whereas bacteria within the phylum Firmicutes show altered
expression toward both directions.
Human Studies
High-risk and UHR individuals who have a higher likelihood of
developing psychosis in the future did not differ in microbialT
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Kraeuter et al. Gut Microbiome in Psychosisrichness, alpha-diversity. However, beta-diversity was altered in
high-risk and UHR individual’s analysis compared to controls.
UHR individuals had increased bacterial abundance at order,
genus, and species levels in the phyla Firmicutes andFrontiers in Psychiatry | www.frontiersin.org 12Bacteroidetes compared to the other groups (4) (Figure 6 and
Table 2). It is important to note that clinically, UHR individuals
showed more severe symptoms and functional impairments on
the Scale of Prodromal Symptoms for screening of schizophrenicFIGURE 2 | SYRCLE’s risk of bias tool.FIGURE 3 | Quality assessment of all animal studies.August 2020 | Volume 11 | Article 799
Kraeuter et al. Gut Microbiome in PsychosisFIGURE 4 | STROBE completeness of reporting analysis of human studies.Frontiers in Psychiatry | www.frontiersin.org August 2020 | Volume 11 | Article 79913
Kraeuter et al. Gut Microbiome in Psychosissymptoms and the Global Assessment of Function Scale,
Modified Version, respectively, than the other two groups (4).
Functional profile analysis using Phylogenetic Investigation of
Communities by Reconstruction of Unobserved States (PICRUSt),
which is a bioinformatics software for metagenomic functional
predictions, predicted that short-chain fatty acids (SCFA) related
to pyruvate synthesis, acetyl-CoA synthesis, and fatty acid
biosynthesis initiation pathways were increased in UHR
individuals compared to high-risk and controls, however only
the acetyl-CoA synthesis pathway was significantly predicted (4)
(Table 2). This profile corresponds with altered glucose
metabolites, which is particularly interesting in the context of
energy metabolism abnormalities that have been recently
identified in schizophrenia [27-30].
Patients with first-episode psychosis, who received a relatively
short antipsychotic treatment (median length of 20 days), showed
no difference in alpha diversity (54) (Figure 6 and Table 2).
Individuals with first-episode psychosis had enrichment in the
phylum Actinobacteria. At class, order, family, genus and species
levels the overall abundance of bacteria were altered in the phyla
Firmicutes, Actinobacteria, Proteobacteria, “Deferribacteres,”
Euryarchaeota, Cyanobacteria, and Chlorobi in patients with
first-episode psychosis compared to healthy controls (54)
(Figure 6 and Table 2). Physically active patients had a reduced
abundance of Firmicutes at family level compared to active,
healthy controls.
At baseline, multiple bacteria were decreased in drug naïve
first-episode schizophrenia at species level belonging to the phyla
Actinobacteria, Proteobacteria, and Firmicutes compared to
controls (55) (Figure 6 and Table 2).
Individuals with chronic schizophrenia with over ten years of
antipsychotic medication were investigated and compared to
healthy controls (57). Gut microbiota samples did not differ in
alpha diversity, microbial richness, and diversity, from healthy
controls. However, they showed differential clustering of microbial
communities of chronic schizophrenic patients compared to
respective controls (beta diversity). Furthermore, healthy controlsFrontiers in Psychiatry | www.frontiersin.org 14showedmore similar bacterial communities, tighter clustering, than
patients with schizophrenia (57) (Figure 6 and Table 2). At
phylum level, Proteobacteria and Fusobacteria were significantly
increased, and Firmicutes were less abundant in schizophrenia
patients compared to controls. At class, order, family, genus, and
species levels bacteria belonging to the phyla Proteobacteria,
Fusobacteria, Firmicutes, Bacteroidetes, Actinobacteria, and
Euryarchaeota were altered in chronic schizophrenia patients
(57) (Figure 6 and Table 2). Furthermore, using PICRUSt
analysis, functional pathways were identified to be altered in
individuals with schizophrenia, such as pathways responsible for
the synthesis of vitamin B6, fatty acid, starch, sucrose, tryptophan,
cysteine, methionine, and linoleic acid metabolism and the
degradation of some xenobiotics (57).
Similar to the aforementioned study (57), no changes in alpha
diversity were found in chronic, medicated patients with
schizophrenia and schizoaffective disorder (56). However, beta
diversity showed a clear separation between the patient and
control populations and showed a wider distribution of
schizophrenia samples (56) (Figure 6 and Table 2). At phylum
level, Proteobacteria were decreased in patients with schizophrenia.
At genus level, bacterial abundance was altered bidirectional in the
phyla Proteobacteria, Proteobacteria, and Firmicutes (56) (Figure 6
and Table 2).
Another recent study has gone beyond just determining the
bacterial abundance in the microbiome in people with schizophrenia
and evaluated if behavioral phenotypes could be transferred through
fecal microbial transplant from patients with schizophrenia to germ-
free mice (40). The gut microbiome of patients with schizophrenia
had reduced alpha diversity compared to healthy controls,
suggesting a lower within-sample diversity. Furthermore, beta-
diversity was also significantly altered in schizophrenia patients
(40) (Figure 6 and Table 2). Bacterial abundance was altered at
family level belonging to the phyla Firmicutes, Bacteroidetes,
Actinobacteria, and Proteobacteria (40) (Figure 6 and Table 2).
Animals, which received elements of the gut microbiome from
patients with schizophrenia via fecal microbial transplants, showedFIGURE 5 | Microbiome methodological consideration.August 2020 | Volume 11 | Article 799
Kraeuter et al. Gut Microbiome in PsychosisFIGURE 6 | Taxonomic tree of schizophrenia. Showing reduced abundance in orange, increased abundance in purple with lighter shades of orange and purple to
signify that only preclinical evidence is available. White-no change only for representative purposes. Ultrahigh-risk individuals †(4), first episode psychosis ^ (54), first
episode schizophrenia “(55), chronic schizophrenia # (57) ∇(56) ∞(40), maternal immune activation model + (53), pharmacological model * (52), social isolation! (46).Frontiers in Psychiatry | www.frontiersin.org August 2020 | Volume 11 | Article 79915
Kraeuter et al. Gut Microbiome in Psychosisa behavioral phenotype that had some overlaps with schizophrenia-
like behaviors, including locomotor hyperactivity, reduced anxiety,
and decreases depression-like behavior, attributed to increased
activity. However, no difference was found in cognitive behaviors
and sociability. Mice, which received fecal matter from individuals
with schizophrenia, showed an increased startle response at high-
decibel tones; however, no difference was found in pre-pulse
inhibition of startle, which has been used extensively as a
translational behavioral biomarker of psychotic states. Investigators
further verified that gut composition was altered through the fecal
microbial transplant and found that the gutmicrobiome significantly
differed compared to that of control mice. The most changed
bacterial families were Aerococcaceae (Phylum: Firmicutes), and
Rikenellaceae (Phylum: Bacteroidetes), which was similar to
changes found in patients with schizophrenia [58].
Overall, the studies highlighted in this review demonstrated
differential changes for all major phyla, including Proteobacteria,
Firmicutes, Bacteroidetes, Actinobacteria, and Fusobacteria in
patients with schizophrenia compared to healthy controls (4,
40, 54–57).DISCUSSION
Diversity of the Gut Microbiome
in Schizophrenia
The diversity of the gut microbiome is unique to each individual.
The majority of publications reviewed here identified no change
in alpha diversity across animal and human studies (4, 46, 52–54,
56, 57). However, one study demonstrated an overall decrease in
alpha diversity in individuals with chronic schizophrenia (40).
The majority of patients were medicated with antipsychotics,
which may have resulted in reduced microbial community
diversity (40), as treatment with an atypical antipsychotic
reduced microbiome community diversity in patients with
bipolar disorder (alpha diversity), which was more profound in
females (61). On the contrary, individuals on antipsychotic
medications had no change in microbial community diversity
(57). Due to conflicting results, we can only speculate that
antipsychotic treatment may have resulted in a decrease in
alpha diversity. Therefore, future studies should investigate the
potential impact of antipsychotic treatment on the gut
microbiome in schizophrenia.
The gut microbiome of patients with psychosis and animal
models of schizophrenia are separated from the microbiota of
healthy control individuals and control animals (beta diversity) (4,
40, 52–54, 56, 57). This clearly demonstrates that the gut
microbiome in psychosis differs from that of the healthy
controls. However, as there is a lack of studies comparing the
microbiome between psychosis and other psychiatric and chronic,
noncommunicable disorders, this does not necessary mean that
the microbiome profile identified in psychosis is diagnostically
specific. Nevertheless, these results, together with data showing
that high-risk and UHR individuals have an altered microbiome
compared to that of healthy controls (4), raise the possibility of
developing the gut microbiome profiling further to be used as partFrontiers in Psychiatry | www.frontiersin.org 16of a biomarker battery to identify individuals at risk for later
development of psychosis.
The studies outlined in this systematic review revealed that
the phyla Proteobacteria (57), Firmicutes (52, 57), Bacteroidetes
(52, 57) Fusobacteria (57), and Actinobacteria (46, 54, 57) were
altered in patients at risk to develop schizophrenia, with chronic
schizophrenia or in animal models of the disease at all different
taxonomic units (Figure 6). First, we will individually discuss
each of these phyla, within each phyla section we are discussing
lower taxonomic units, and consider the functional implications
that might be associated with their change.
Proteobacteria
Altered abundance, in both directions, of Proteobacteria has
been associated with obesity, inflammation, and altered gut
permeability (62–65). Proteobacteria were increased (57), as
well decreased (56) in patients with chronic schizophrenia
(Figure 6 and Table 2) in the gut microbiome, but not in the
oropharynx microbiome (66), which suggests that the imbalance
of Proteobacteria abundance are specific to the gut microbiome.
While an increased abundance of Proteobacteria is associated
with the neonatal period (67), gastric bypass surgery (62, 68), and
disease states such as metabolic disorders (69) and intestinal
inflammation (70), decreased abundance of Proteobacteria have
been found in overweight individuals (62). One study identified
no difference in body mass index (57), whereas, in another study,
individuals with schizophrenia had a significantly higher body
mass index compared to healthy controls (56) (Table 2). Weight
may have been a contributing factor influencing the abundance
of Proteobacteria. Possibly, the decrease in Proteobacteria is more
representative of patients with psychosis, because they tend to be
more overweight or obese compared to mentally healthy controls
(71). Therefore, future studies need to include lifestyle factors,
such as diet, as potential covariates in the data analysis. At family
level, both increased (57) and decreased (40) abundance of
Enterobacteriaceae have been found (Figure 6 and Table 2).
An increase in Enterobacteriaceae have been associated with
obesity (63), inflammation (64) and a “leaky gut” (65); however,
obesity could not have been the driver for the change of this
bacterial family as individuals with schizophrenia in both studies
were in the healthy weight range based on their body mass index
(40, 57). Increased gut permeability has been suggested to be
related to schizophrenia (72) and may have been a contributing
factor for the increase in Enterobacteriaceae (57). Besides, patients
with schizophrenia show higher levels of proinflammatory
cytokines (73). It is unclear, however, if the increased abundance
of Enterobacteriaceae (57) was driven by proinflammatory
cytokines or increased gut permeability in schizophrenia.
Firmicutes
An increased abundance of Firmicutes has been associated with
an unhealthy dietary pattern, such as western diet and obesity (5,
74). A higher abundance of Firmicuteswas found in the oropharynx
microbiome of patients with schizophrenia (66). Animals injected
with phencyclidine, a pharmacological model of schizophrenia,
showed an increase in Firmicutes in their gut microbiome (74). In
contrast, Firmicutes were less abundant in patients with chronicAugust 2020 | Volume 11 | Article 799
Kraeuter et al. Gut Microbiome in Psychosisschizophrenia (57) (Figure 6 and Table 2). At class, order and
family levelsNegativicutes, Selenomondales, andVeillonellaceaewere
reduced in first-episode psychosis (54) but were increased in an
animal model of social isolation (46). Veillonellaceae were also
increased in chronic schizophrenia (40, 57) (Figure 6 and Table
2). Patients with chronic schizophrenia showed both an increase
and a decrease in the genus Clostridium (56) in different studies
(Figure 6 and Table 2). Interestingly, an increase in this genus is
associated with risperidone treatment (75). At this point, we are
unable to conclude about the potential role of risperidone treatment
as both studies (56, 57) report antipsychotic use, without specifying
the type of medication used. Several species of Clostridium are
precursors of 4-ethylphenylsulfate (76), whichmay contribute to the
pathophysiology of schizophrenia, as it is important in pheromonal
communication in mice under the control of testosterone levels
(77). Serum 4-ethylphenylsulfate was elevated in MIA animals, a
neurodevelopmental model of schizophrenia and 4-ethylphenylsulfate
induced an anxiety-like behavioral phenotype, which may suggest
behavioral abnormalities may be related to 4-ethylphenylsulfate
produced by Clostridium (53). At species level, first-episode
psychosis (54) and chronic schizophrenia patients (57), show
similar to a study in oropharyngeal samples of schizophrenia
patients, a significantly increased abundance of Lactobacillus
phage phiadh (78) (Figure 6 and Table 2).
Bacteroidetes
Bacteroidetes were increased in the pharmacological model of
schizophrenia (52) and patients with chronic schizophrenia (57)
(Figure 6 and Table 2). Stress is involved in the pathophysiology
of psychotic disorders, such as schizophrenia (79). In a mouse
model of stress, mice were subjected to an aggressive male mouse
within their home cage to induce stress. Investigators found
elevated levels of the genus Bacteroides (80), which was
demonstrated in chronic schizophrenia (57) (Figure 6 and
Table 2). Treatment with the probiotic Bacteroides fragilis was
shown to improve anxiety-like, repetitive and communicative
behaviors, and sensorimotor gating in the MIA model (53) (Table
2). Bacteroides fragilis improved anxiety-like (57), repetitive (57)
and communicative behaviors (57), sensorimotor gating (57);
however, Bacteroides fragilis do not influence social behaviors (53)
(Figure 6 and Table 2). Depressive-like symptoms in chronic
schizophrenia patients were associated with an increased
abundance of Bacteroides (56).
Actinobacteria
Actinobacteria are increased in first-episode psychosis, chronic
schizophrenia, and socially isolated animals (46, 54, 57) (Figure 6
and Table 2). Tropheryma, which belong to the phyla
Actinobacteria, most studied species is Tropheryma whipplei, has
been associated with intestinal malabsorption (81). Tropheryma
whipplei was significantly increased in patients with first-episode
psychosis (54) (Figure 6 and Table 2). At genus level, Collinsella
was elevated, which produces proinflammatory cytokines such
as interleukin-17a and altered intestinal permeability in arthritis
(82). Patients with schizophrenia show alter gut permeability (83).
Additionally, multiple studies have found increases IL-17a plasmaFrontiers in Psychiatry | www.frontiersin.org 17concentrations in naïve first-episode schizophrenia patients
(84, 85).
In conclusion, the published literature indicates that
schizophrenia, both first-episode and chronic, is associated
with microbiota changes, as shown by beta diversity, that will
distinguish them from healthy controls. In this systematic review
we included studies in which healthy controls were compared to
either individuals at risk to develop psychosis or with diagnosed
psychosis (either first episode or chronic). Such cross-sectional
design, together with a variety of cofounding factors, which were
controlled for in some, but not in all cases, precludes us from
concluding about causality. However, our review of the available
human literature clearly indicates the existence of an association
between different stages of psychosis and the gut microbiome.
Future studies will be required to identify the primary drivers of the
microbiome alterations in psychosis and the potential direction of
causality between gut microbiome changes in psychosis.
Methodological Considerations
Cofounding Factors
Within the reviewed publications gender was not addressed as a
potential cofounding varible, which can potentially affect the gut
microbiome. A review investigated gender differences in the gut
microbiome and concluded that gender effects are inconsistent
and identified that differences in geography, life style, diet, age,
genetics, and potential other factors contribute more extensively
to alterations in the gut microbiome (86). Within the reviewed
articles, we reviewed populations from different geographical
locations, which may have contributed to observed differences in
microbiome. However, all studies demonstrated a clear
separation between matched controls and psychotic individuals
controlling for geographical location. Another major cofounding
variable is age. We observed a broad age range in the reviewed
studies, which may be expected considering that we included
studies reporting on at-risk, UHR as well as on chronic
schizophrenia. It has been suggested that age might be a major
contributor to alterations in the gut microbiome (87). Gut
microbiome changes within the elderly are associated with
physiological changes within the gastrointestinal tract and has
been demonstrated to reduce over time in diversity, shifts in
dominant species, a decline in beneficial bacteria and decreased
availability of beneficial metabolites such as short chain fatty
acids (88). Older individuals have lower levels of Firmicutes and
increased abundance of Proteobacteria (88). It is difficult to
establish the potential cofounding effect of age on the results
presented in the review. It should be noted, however, that each
study contained age-matched controls, just like in the case of
geographical location.
Fecal Sample Methodology Cofounders
We demonstrated that the CoR was greater in human studies
allowing for greater comparability between studies. However,
animal studies lacked reporting and should therefore be
interpretate carefully. Overall, alterations and lack of reporting can
be potential cofounding factors [further extensive review elsewhere
(42)]. Methodological difference should be standardised in theAugust 2020 | Volume 11 | Article 799
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and would allow for improved interpretation of data.
Factors Potentially Contributing to the
Altered Microbiome in Psychosis
In the following section we address potential factors influencing
the gut microbiome in individuals with psychosis. Due to the
heterogeneous nature of psychotic disorders no specific and
unique factors to leading to psychosis are known. Therefore,
we considered common life-style and environmental factors,
genetic susceptibility and medication use that can potentially
influence the gut microbiome in psychosis, as well as in other
serious mental illness.Environmental Factors
Early Life Events
Children will receive the first inoculum from their mothers (89).
Mode of delivery can influence the gut microbiome (37). Offspring
will receive during vaginal birth microbes found in the maternal
vagina and feces (89). Whereas, during Cesarean delivery (C-
section), most microbes colonizing the gut are from external body
surfaces (89). C-section significantly decreases Bifidobacteria spp.
(90) and increases Staphylococcus, Streptococcus or Propionibacteria
(91, 92). However, the differences in microbiota between C-section
and vaginal birth gradually disappear over time (37). Preterm birth
will result in an increased abundance of Proteobacteria and a lack of
Bifidobacterium and Lactobacillus at genus level (37). It has been
established that early life events are potential risk factors for
schizophrenia (93, 94). C-section and preterm birth have been
linked as a risk factor for schizophrenia (93, 94). Bifidobacterium
spp., which is in line with the microbial profile of C-section and
preterm birth, were decreased in first-episode psychosis patients
(55) (Figure 6 and Table 2). Chronic schizophrenia patients had
increased levels of Proteobacteria at phylum level, which is related to
preterm birth (57) (Figure 6 and Table 2). In first-episode
psychosis, UHR and chronic patients with schizophrenia
Lactobacillus, which is again related to preterm birth, was
increased (4, 54, 57) (Figure 6 and Table 2).
These early life events seem to alter the gut microbiome and
may influence the development of psychosis later in life, perhaps
through brain development influenced by the microbiome.
Future research should specifically investigate if the changes in
the microbiome due to the aforementioned factors contribute to
the development of psychosis.
Stress
It has long been established that stress and the activity of the
hypothalamus-pituitary-adrenal (HPA) axis can alter the
composition of the gut microbiome (39). Maternal
separation, a model of stress, results in prolonged HPA
activity, which resulted in rhesus monkeys (95), rats (96) in
altered microbiome composition (95). Chronic restraint stress in
adult mice resulted in differential gut microbiota composition
compared to nonstressed mice (80). Stress decreased Bacteroides
spp. and increased Clostridium spp., which was accompanied by
an activation of the immune system and a “leaky” gut (97),Frontiers in Psychiatry | www.frontiersin.org 18allowing for the translocation of luminal content such
as lipopolysaccharides.
Stress is involved in the development of psychotic disorders such
as schizophrenia (79, 98). Life events perceived as stressful can
increase the occurrence of psychotic episodes (99). Individuals with
schizophrenia experience stress more intensely; therefore even
minor everyday stressors might exacerbate positive symptoms
(100, 101). Management of day-to-day stress can be used in the
management of psychosis (102); however, this intervention, in
combination with antipsychotics, is only partially protective (103).
This hypersensitivity to stress might be attributed to inappropriate
autonomic nervous system and HPA axis function (79). Psychosis
itself is a stressful event for the body, activating the stress response
(98). Hypercortisolemia has been shown in patients with
schizophrenia (104), which has been linked to the negative
symptoms of schizophrenia (79). However, increased cortisol
levels are not consistently found in individuals with schizophrenia
(105). A meta-analysis found dysregulation of cortisol in psychotic
patients (106). Allostatic load is the adaptation in response to
stimuli such as stress (98). An increased allostatic load was seen
in first-episode psychosis and schizophrenia patients compared to
controls (98). This study found a positive correlation between
positive symptoms with allostatic load in schizophrenia
patients (98).
The genus Clostridium was increased in animals treated with
phencyclidine (52) and chronic schizophrenia patients (57);
however, Clostridium also decreased in chronic schizophrenia
patients (56) (Figure 6 and Table 2), consistent with a stress
response. However, the stress level of schizophrenia patients was
not described, and therefore it is unknown if the microbiota was
altered due to increased stress or visa versa (57). A decrease in
Bacteroides spp. is associated with stress (97), while in chronic
schizophrenic patients, this genus was decreased (57) (Figure 6
and Table 2).
In conclusion, based on the limited data available, it is difficult
to establish if stress altered the microbiome. Future studies should
assess stress levels and allostatic load to understand the impact of
stress in psychosis on the gut microbiome.
Infectious Agents
Infectious agents, such as Toxoplasma gondii, have been suggested
to contribute to the development of schizophrenia (107, 108). It
has been recently demonstrated in a preclinical study that chronic
Toxoplasma gondii infection results in an enrichment of
Bacteroidetes in CD1 mice compared to noninfected controls
(109). Interestingly, Bacteroidetes were also increased in a
pharmacological model of schizophrenia (52) and in individuals
with chronic schizophrenia (57). However, on the basis of the
available evidence it is not possible to conclude about causality of
the link between Toxoplasma gondii infection, alteration in the gut
microbiome and the development of schizophrenia.
Lifestyle Factors
Diet
Diet is shaping the composition of the gut microbiome (5).
The gut microbiome, in turn, is important in metabolizing the
ingredients of food (18) and host fat storage, through theAugust 2020 | Volume 11 | Article 799
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the lumen of the gut, promoting hepatic lipogenesis by fasting-
induced adipocyte factor suppression (110). Multiple studies
have demonstrated that altering diet rapidly changes the gut
microbiome (5, 111) and microbial beta-diversity (112). Early life
nutrition, through changing the gut microbiome, is important in
the infant’s development (113). Different diets in adulthood have
been shown to modulate the gut microbiome, such as a high-
protein, reduced carbohydrate diet (114), ketogenic diet (115),
high fat, high sugar diet (western diet) (116, 117), and
mediterranean diet (118). This indicates the strong impact of
diet on the gut microbiome.
Nutrition is an important factor in schizophrenia due to poor
dietary choices, causing obesity and secondary diseases (119).
Obesity is twice as likely in schizophrenia/psychosis compared to
the general population, affecting more than 50% of schizophrenic
individuals (120). Drug naïve patients with schizophrenia show
higher rates of obesity and type II diabetes compared to healthy
individuals (120). Patients with schizophrenia consumed more
fat (121, 122), saturated fat (122, 123), proteins (122),
carbohydrates (122) and less fiber (121), than healthy controls.
However, it was found that similar choices were made, but the
overall food consumption was increased compared to healthy
controls (122). Overall, people with psychosis tend to prefer
unhealthy, fast food-type foods (120). This results in a dietary
pattern high in saturated fats and sugars (“Western” diet).
However, the gut microbiota of schizophrenia patients did not
reflect that of individuals on a Western diet, characterized by a
decrease in Bifidobacteria, Bacteroides, and Prevotella and an
increase in Firmicutes (5). Within this review, first-episode
psychosis had an increased abundance in Bifidobacteria (54)
(Figure 6 and Table 2). Different food types were not
significantly associated with clustering of the microbiota (54).
Increased Prevotella were found in UHR individuals (4);
however, no conclusion can be drawn on the impact of
nutrition as no metabolic or nutritional assessments were
reported. In chronic schizophrenia patients, Firmicutes
decreased, and the abundance of Bacteroides and Prevotella
increased (57). It has to be noted that individuals in that study
were Chinese patients, who did not show metabolic symptoms
commonly seen in schizophrenia. This lack of weight gain has
previously been reported in other Chinese schizophrenia patients
(124). One study predicted an altered glucose metabolism (4),
which is particularly interesting in the context of energy
metabolism abnormalities that have been recently identified in
schizophrenia [27-30]. A review investigated the link between
the gut microbiome and glucose metabolism and found that the
gut microbiome has substantial influence on glucose homeostasis
through short chain fatty acids, bile acid metabolism, hormone
secretion and synthesis of amino acids (125). However, future
studies should address this point in individuals with psychosis to
better understand the relationship between the gut, brain and
energy metabolism.
In summary, individuals with psychosis show unhealthy dietary
choices, which may influence the gut microbiome. However, the
microbiome profiles described in studies on patients with psychosisFrontiers in Psychiatry | www.frontiersin.org 19do not support this notion. Nevertheless, at this point we can
neither prove nor disprove the influence of diet to influence the gut
microbiome in psychosis due to conflicting evidence and lack of
reporting of dietary habits in these studies. Future studies should
incorporate dietary patterns to be able to make a more definitive
conclusion on the effects of dietary factors on the gut microbiome
in individuals with psychosis.
Exercise
Exercise can impact microbial abundance in animals (126) and the
human gut (127–131). The gut microbiota is different between
sedentary individuals and people performing physical exercise (129,
132). Exercise reduced Bacteroidetes (129, 130) and Proteobacteria
(132). Activity increased the undefined genus in the S24-7 family
(129), Verrucomicrobia (132), Bifidobacteriaceae (132),
the Streptococcaceae family (129) and Firmicutes (130), compared
to sedentary controls. In sedentary woman bacteria belonging to the
families, Barnesiellaceae and Odoribacteraceae were more abundant
compared to active women (130).
Individuals with schizophrenia and other psychotic disorders
are significantly less physically active than healthy individuals,
and are also less active then patients with other psychotic
disorder (133, 134). Patients with chronic schizophrenia show
an increased abundance in Bacteroidetes and Proteobacteria and
a decreased abundance in Streptococcaceae and Firmicutes (57)
(Figure 6 and Table 2), which could possibly be mitigated by
exercise as active individuals have opposing abundances (129,
130, 132). Further supporting this argument, Firmicutes were
increased in phencyclidine treated animals (52), which could
have been related to hyperactivity induced by the phencyclidine
administration. The increase in the phylum Bacteroidetes is
associated with a sedentary lifestyle (130). Bacteroidetes were
increased in chronic schizophrenia patients (57) (Figure 6 and
Table 2); however, this increase was as well seen in the
phencyclidine, hyperactive animals (52) (Figure 6 and Table
2). Therefore, it is unclear at this stage if physical activity altered
the gut microbiome. The activities of patients with schizophrenia
are not explicit in the publications reviewed here. Nevertheless,
physical activity has been considered to influence the gut
microbiome composition in the context of schizophrenia
Schwarz, Maukonen (54). Pateints with first-episode psychosis,
stratified for amount of exercise, demonstrated an increased
abundance of Lactobacillaceae and decreased abundance of
Veillonellaceae at family level in physically active, first-episode
psychosis individuals compared to physically active, healthy
controls (54) (Figure 6 and Table 2). Future studies need to
assess physical activity levels as a potential cofounder to
influence the gut microbiome.
Smoking
Environmental contaminants, such as smoking, influence the gut
microbiota (135). Furthermore, smoking can lead to DNA damage
and epithelial cell methylation (136), resulting in altered gut
function and possibly altered microbiota composition. Smoking
increased within-participant diversity, Dialister invisus, and
Megaspaera micronuciformis were more abundant in the upper
gastrointestinal tract in current smokers compared to the ones whoAugust 2020 | Volume 11 | Article 799
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Bifidobacteria and SCFA, such as propionic and butyric acid
(137), and increased Lachnospiraceae spp. (138). Passive smoking
increases Clostridium spp. and reduces Firmicutes and
Enterobacteriaceae in animals (139). In humans smoking
increased Clostridium (140), Bacteroidetes, and Proteobacteria
(141) and decreased Firmicutes and Actinobacteria (141).
Smoking is more prevalent in individuals with schizophrenia
than in healthy individuals (142).
As reviewed above, in first-episode psychosis, Bifidobacteria
were increased (54) (Figure 6 and Table 2), whereas smoking
decreased this bacteria. However, this study did not specify
smoking status (54). In human studies, Lachnospiraceae (57)
and Firmicutes (57) were decreased (Figure 6 and Table 2).
Decreased Firmicutes are in line with smoking; however, in
patients with chronic schizophrenia, tobacco usage was not
different compared to healthy control (57). At genus level
contradictory results were found for Clostridium, however as
mentioned before an increase in Clostridium, which is associated
with smoking, was seen both in an animal model of
schizophrenia (52) and in patients with chronic schizophrenia
(57), where no difference in tobacco usage was seen between
patients and controls. On the contrary, patients with
schizophrenia, who were significantly likelier to smoke, had
decreased abundance of Clostridium (56) (Figure 6 and Table
2). Enterobacteriaceae were increased in chronic schizophrenia
patients (41) (Figure 6 and Table 2), which would be in line with
possible tobacco usage; however, smoking status was not
reported within that study.
In conclusion, according to the studies reviewed here
individuals with schizophrenia either did not smoke more than
the general population, or tobacco usage was not reported, except
Nguyen, Kosciolek (56) where contradictory results were found
with regards to smoking and the gut microbiome. Considering
animal models of psychosis that do show altered gut microbiome
despite the lack of smoking exposure, one can argue that the
change in the gut microbiome seen in individuals with psychosis
is likely to be independent of smoking status. However, most
studies did not report smoking status, which predicts a firm
conclusion regarding the link between smoking status and
altered gut microbiome at this stage. Future studies should
report smoking status and investigate if tobacco usage might
be a cofounding factor influencing the gut microbiome.
Overall, although it has been widely acknowledged that life style-
factors are essential in shaping the gut microbiome, the studies
covered in this systematic review do not support the notion that the
difference in the gut microbiome between controls and individuals
with psychosis is causally related to lifestyle factors. Potentially,
lifestyle factors, such as diet, exercise, and smokingmay improve the
gut microbiota of individuals with psychosis. Therefore, the
completeness of reporting to provide a detailed account of the
lifestyle factors is of great importance for future studies.
Genetics
Host genetic variation can influence the diversity of the gut
microbiome (143). However, the relationship between host
genetics and gut microbiota is largely unknown (143).Frontiers in Psychiatry | www.frontiersin.org 20Although, lifestyle factors such as diet and exercise will
contribute to similar gut microbiota composition of close
relatives, suggesting that genetics might be an important factor
(143). For example, monozygotic twins share a more similar gut
microbiota profile than dizygotic twins (143).
Genetic factors are important in the etiology of psychotic
disorders such as schizophrenia (144). At this stage, no studies
have investigated the effect of host genetic variation in individuals
with schizophrenia on the gut microbiota. Therefore, we can only
speculate that variations of bacterial abundances found in this
population may be due to genetic variation involved in the
pathogenesis of psychosis. Future studies should incorporate
genetic analysis to understand the importance of host genetic
variation on the gut microbiome.
Antipsychotics
Antipsychotics are the primary medications used for the
management of schizophrenia (145). However, the knowledge
of the effects of antipsychotics on the gut microbiome is currently
in its infancy. Antipsychotic use can cause severe metabolic side
effects such as weight gain, increased visceral fat, and glucose
dysregulation (146), of which the mechanism of action is not
fully understood (146). It is believed that the convergence of
central and peripheral mechanisms are involved in metabolic
side effects (146). It has been demonstrated that the composition
of the gut microbiome is linked to obesity (147). Olanzapine
treatment increases body weight (146, 148) and leads to a shift of
the gut microbiome, which involves the increase of the phylum
Firmicutes (146, 148) and decreases in the phyla Bacteriodetes
(146, 148) in rodents. In female rats, olanzapine reduced the
abundance of Actinobacteria and Proteobacteria compared to
controls (148). Another study found an increase in
Erysipelotrichia and Gammaproteobacteria and a reduced
abundance of Bacteroidia at class level (149). Olanzapine
inhibited the growth of Escherichia coli NC101 (149). One
study found no change in microbial composition after
olanzapine treatment, which may have been due to the short
duration of treatment (150). However, this study demonstrated
that acetate concentration changed, suggesting that olanzapine
did affect on this by-product of the microbiome function (150).
Risperidone increased Firmicutes, where Lactobacillus spp. were
reduced, and decreased Bacteroidetes, where Bacterioides spp.
were increased and Alistipes spp. decreased and Proteobacteria in
female C57BL/6J mice compared to controls (151). The most
abundant genera were Allabaculum spp. in risperidone treated
animals compared to controls (151). Risperidone treatment
resulted in weight gain (151). Transplant of fecal matter of
female C57BL/6J mice on risperidone treatment to naïve mice
resulted in a decreased resting metabolic rate, which may have
contributed to the increase in body weight (151). Donor fecal
matter was analyzed for risperidone concentration, which was
10-fold less than to establish a dose-response curve (151).
Therefore, investigators concluded that the microbiota of
risperidone treated animals was the obesogenic factor rather
than the remaining risperidone within donor fecal samples (151).
In medically healthy males, risperidone treatment led to weight
gain with an altered gut microbiome compared to psychiatricallyAugust 2020 | Volume 11 | Article 799
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similar to the gut microbiota changes after olanzapine
administration. Antipsychotic treatment increased the abundance
of Lachnospiraceae and decreased the abundance of Akkermansia
after adjustment for body mass index in patients with bipolar
disorder (61). However, Akkermansia was less abundant in
nonobese, antipsychotic-treated patients (61). One publication
covered in this systematic review assessed the changes in first-
episode schizophrenia after 24-weeks of risperidone treatment (55).
Chronic risperidone treatment altered metabolic parameters such
as an increase in weight, body mass index, fasting serum glucose
levels, triglycerides, and low-density lipoproteins (Table 2).
Risperidone treatment increased Bifidobacterium spp. and
Escherichia coli and decrease the abundance of Clostridium
coccoides and Lactobacillus spp. (55) (Figure 6 and Table 2).
Oxytocin
As the ever evolving literature recognizes the need for new drug
treatments to complement the presently used antipsychotic
medication, the neuropeptide oxytocin has been suggested as a
potential novel treatment approach (152). Evidence from preclinical
and clinical studies suggest therapeutic effects on all symptom
domains of schizophrenia, with particular improvement in the
negative symptoms (152). A potential link with the microbiome
is suggested by the finding that the bacterium Lactobacillus reuteri
upregulates oxytocin (153). One study we presented in this
systematic review in first episode psychosis patients showed an
increased abundance of Lactobacillus reuteri (54). However, the
exact details of the interaction between oxytocin and the
microbiome are currently unknown.
In our systematic review, six articles assessed different stages
of the development of schizophrenia, such as high-risk, UHR,
first-episode psychosis, first-episode schizophrenia, chronic
schizophrenia. High-risk, UHR, and first-episode schizophrenia,
first-episode psychosis patients were at study onset drug naïve (4,
54, 55). For chronic patients, antipsychotic treatment had to be
more than six months of use. Therefore, changes might be
cofounded by antipsychotic treatment (40, 56, 57). More studies
are needed to identify the influence of antipsychotic medication
on the gut microbiome.
Functional Implication of the Change in
Microbiota on the Psychopathology of
Psychosis
Symptoms of Psychosis and the Gut Microbiome
Of the publications reviewed here, some have linked the gut
microbiome to symptoms seen in schizophrenia. In the
pharmacological model of schizophrenia, hyperactivity was
associated with an increase in Lachnospiraceae and Clostridiaceae
and at genus level an increase of Roseburia, Clostridium, and
Odoribacter (52) (Figure 6 and Table 2). In socially isolated
animals, activity was positively correlated with the abundance of
Bacillales. On the other hand, Clostridales was negatively correlated
with locomotor activity (46). Socially isolated animals had
increased locomotor activity in conjunction with reduced
Clostridales (46). Furthermore, Clostridiales was negativelyFrontiers in Psychiatry | www.frontiersin.org 21correlated with cognitive performance (46). Additionally, taxa
belonging to the order Clostridales, at family level Ruminococcaceae
and genus level Papillibacter were positively correlated to anxiety-like
behaviors (46). Bacillales were negatively correlated to anxiety-like
behaviors. Impaired contextual fear task, which investigates the
associative learning process, was associated with an increase in
Veillonella and Defluvitaleaceae UCG-011 (46).
In people with schizophrenia, negative symptoms were
related to decreased Ruminococcaceae, and self-reported
mental well-being was positively correlated with the phylum
Verrucomicrobia (56). Correlation analysis revealed that age of
disease onset positively correlated with Cyanobacteria at
phylum level, indicating that the earlier the disease onset, the
higher the abundance of Cyanobacteria. Depressive-like
symptoms were associated with an increased abundance of
Bacteroides . Veillonellaceae OTU191 were negatively
correlated with the Positive and Negative Syndrome
Scale (40). On the other hand, Bacteroidaceae OTU172,
Streptococcaceae OTU834, and two Lachnospiraceae OTUs
(477 and 629) were positively correlated with PANSS (40).
Bacterial numbers of Lactobacillus group, Lachnospiraceae,
Ruminococcaceae, and Bacteroides spp. were correlated with
symptom severity, particularly for negative symptoms and
poorer functioning (54). Positive symptoms were correlated
with bacteria of the Lactobacillus group (54).
Systemic biochemical changes and their relationship with the
gut microbiome have been investigated. It was identified that
Blautia, Coprococcus, and Roseburia were negatively associated
with vitamin B6, taurine, and hypotaurine metabolic pathway
and positively associated with methane metabolic pathways (57).
Increased inflammatory cytokines have been seen in patients
with schizophrenia (73). Hippocampal IL-10 and IL-6 correlated
with Peptostreptococcaceae positively (46), while Bacillales
correlated negatively with hippocampal IL-6 (46, 54). Interestingly,
if the microbial composition offirst-episode psychosis clustered with
controls, these patients were more likely to show remission (70% of
patients) (54). However, patients with abnormal microbial
composition at baseline showed low remission rates (28% of
patients) (54). Analysis revealed that this remission was not due
to symptom severity at baseline (54). Clustering was not influenced
by physical activity, body mass index, type of psychosis, duration of
antipsychotic treatment, and the food consumed one week before
fecal sample collection (54).
In summary, the abundance of specific bacteria correlated
with behaviors and biochemical changes. This raises the
possibility of targeted treatment approaches, such as pre/
probiotics, to alleviate individual symptoms, however at this
point in time causation has not been established. Further studies
are required to link individual behaviors and biochemical
changes in psychosis to the gut microbiome.Does the Microbiome Have a Pathogenic
Role in Psychosis?
To address this question, we investigated retrospective studies
to see if antibiotic use increased the prevalence of psychosis. A
nationwide, register-based cohort study in Denmark outlinedAugust 2020 | Volume 11 | Article 799
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which was independent of age, compared to antivirals and
antimycotics (154). The risk for mental disorders increased in a
dose-dependent manner, were a risk for mental disorders were
more likely in individuals with more treated infections (154).
The study showed that anti-infective agents were associated
with an increased risk for schizophrenia spectrum disorders
(154). Another study investigating the same Danish cohort
identified that maternal infection during pregnancy treated
with anti-infective agents increased the risk of mental
disorders in the offspring, compared to offspring without
maternal infection with anti-infective agents during
pregnancy (155). The risk of mental health was increased if
maternal infection treated with anti-infective medications
occurred during the second and third trimester (155). It can
be argued that maternal infection during pregnancy is known to
be a risk factor to develop schizophrenia (156). However,
Lydholm, Kohler-Forsberg (155) demonstrated that mental
health disorder risk increased in response to maternal
prescriptions during and after pregnancy. These recent
studies suggest that antibiotic treatment during pregnancy
and later in life may result in the later onset of schizophrenia.
However, these studies are merely observational and would
need further research to create causality.
Interestingly, animals, which received gut microbiome from
patients with schizophrenia via fecal microbial transplant, showed
a schizophrenia-like behavioral phenotype (40). Investigators
further verified that gut composition was altered through the
fecal microbial transplant and found that the gut microbiome
significantly differed compared to that of control mice and was
similar to that of patients with schizophrenia (40). Furthermore,
the gut microbiota was altered in UHR individuals (4). Therefore,
the changes in gut microbiota composition may contribute to the
development of the disease pathophysiology. If confirmed, this
raises the possibility to utilize the gut microbiome as an early
biomarker for schizophrenia spectrum disorders.
Further research should be directed toward the understanding of
bacteriophages, viruses that infect bacteria leading to the death of
the bacteria or integration of the phage into the gut microbiome
(78). Interestingly, a significantly increased abundance of
Lactobacillus phage phiadh has been identified at species level in
first-episode psychosis (54) and in patients with chronic
schizophrenia (57), as well as in the oropharyngeal microbiome
samples of patients with schizophrenia (78) (Figure 6 and Table 2).
However, the importance of bacteriophages is currently unknown
and will require further investigation.
If alterations in the gut microbiome do indeed play a
pathogenetic role in psychosis, agents, which modify the gut
microbiome, can be considered as a potential modifiers of the
disease process in schizophrenia. No research to date has
investigated the effects of pre-or probiotics, antibiotics, fecal
microbial transplant, or dietary intervention on the gut
microbiome, specifically in people with schizophrenia. Bacteroides
fragilis, a probiotic, in MIAmodel of schizophrenia in mice resulted
in the restoration of gut permeability, gene expression, and IL-6 in
the colon and normalized at family level Lachnospiraceae andFrontiers in Psychiatry | www.frontiersin.org 22unclassified Bacteroidales (53). Behaviorally, Bacteroides fragilis
improved anxiety-like, sensorimotor, repetitive and
communicative behavior; however, Bacteroides fragilis treatment
did not affect sociability and social preference in MIA mice (53).
Similar behavioral effects were found with Bacteroides
thetaiotaomicron, whereas Enterococcus faecalis did not improve
anxiety-like and repetitive behavior (53). Therefore, probiotic
treatment might be a novel treatment for schizophrenia by
improving gut functioning. However, a current review comes to
the conclusion that the most recent evidence does not yet support
the use of probiotics for the treatment of psychiatric disorders and
more research is needed (157). Fecal microbial transplant, first
performed approximately 1700 years ago (158), has not yet been
described in either animal models or individuals with schizophrenia,
but has been trialed for multiple sclerosis, patients showing
normalization of neurological symptoms (159). These promising
results may open up a new area in which the therapeutic effects of
the microbiome can be taken advantage of. However, clinical trails
are needed as currently only speculations can be made.
The antibiotic minocycline, which exerts neuroprotective and
anti-inflammatory actions through supressing microglia activation
and the modulation of excitatory neurotransmission, have attracted
attention as potential treatments for schizophrenia, as shown by a
number of small pilot studies with encouraging results (160).
Although, a recent, large, randomized, placebo controlled clinical
trial has provided unequivocal results showing no measurable
therapeutic benefit on negative and other symptoms in patients
with schizophrenia spectrum disorders (161), it has to be
emphasized that active neuroinflammation involving microglial
activation and neuropathology was unlikely to be present during
the first years of schizophrenia, potentially explaining the lack of
effect. The involvement of the gut microbiome in the mediation of
the effects of minocycline has not been investigated.
Lastly, it is feasible to assume that diet could shift and
normalize the gut microbiome in individuals with psychosis.
The high fat, low carbohydrate ketogenic diet modifies the gut
microbiome in an animal model of autism (115). Ketogenic diet
increased Enterobacteriaceae and decreased Firmicutes, Lactobacillus
spp., and Roseburia (115), which were altered in schizophrenia
(Figure 6 and Table 2). We have recently reported that ketogenic
diet improves schizophrenia-like behaviors in an animal model of
schizophrenia (162, 163), which can be due to the diet-induced
alterations of the gut microbiome.CONCLUSION
Overall, the studies covered by this systematic review demonstrate
that the gut microbiome in patients with schizophrenia spectrum
disorders and animal models of schizophrenia is different from
the microbiome of healthy controls. Once these initial findings
are replicated and further extended in different patient
populations the changes in the microbiome might be used as
an independent biomarker of psychosis for high-risk and UHR
individuals. While lifestyle factors do shape the gut microbiome,
it is currently uncertain how they contribute to psychosis.August 2020 | Volume 11 | Article 799
Kraeuter et al. Gut Microbiome in PsychosisLifestyle changes such as diet, exercise, and cessation of smoking
may influence the gut microbiome positively in individuals with
schizophrenia. Stress and other early life events are possible further
environmental factors contributing to this change. Multiple
pathways by which alterations in the gut microbiome may have
occurred, such as inflammation, the vagus nerve communication,
stress response, and metabolites produced by the microbiota have
been reviewed elsewhere (1, 5, 22). Clearly, more research is needed
to clarify the role of specific host extrinsic and intrinsic factors and
to identify specific mechanistic links, if any, between the gut
microbiota and psychosis. Animal and human studies showed
both similarities and differences in gut microbiota composition,
which reflect the well-known difficulties to translate between
preclinical and clinical research in the area of psychosis. Greater
understanding and reporting of methodology of the gut
microbiome will improve translatability from murine to
human studies.
We conclude that the gut microbiome changes may precede the
appearance of the diagnostic clinical symptoms of schizophrenia
spectrum disorders and may contribute to the disease
pathophysiology and the development of the behavioral
symptoms. Further rigorous, well reported preclinical and
longitudinal, mechanistically oriented clinical studies are needed to
provide more evidence to support these potential links. Normalizing
the altered gut microbiome with diet, pre- or probiotics, fecal
microbiome transfer, or pharmacological interventions, may lead
to improved symptom control and mitigation of the metabolic sideFrontiers in Psychiatry | www.frontiersin.org 23effects of antipsychotic medication. However, randomized controlled
clinical trials are urgently required to substantiate the potential use of
targeting the microbiome as a novel therapeutic intervention in
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